SERMs and SERMs with estrogen for postmenopausal osteoporosis

Reviews in Endocrine and Metabolic Disorders

Volumn 11, Issue 4, 2010, Pages 253-259

  Bolognese, Michael A ^a,b  

^a Bethesda Health Research   (United States)

^b SUBURBAN HOSPITAL   (United States)

Author keywords

FRAX; Osteoporosis; SERMs; Tissue selective estrogen complex (TSEC)

Indexed keywords

ACOLBIFENE; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CENTCHROMAN; CONJUGATED ESTROGEN; DROLOXIFENE; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; IDOXIFENE; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PIPENDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; BONE DENSITY CONSERVATION AGENT;

ADJUVANT THERAPY; AGED; AGING; BONE; BRAIN TOXICITY; BREAST; BREAST CANCER; BREAST METASTASIS; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COGNITION; COMPLIANCE [(]PHYSICAL[)]; COST; DISABILITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EDEMA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ENURESIS; FEMALE; FRACTURE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART; HEART INFARCTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; JAW OSTEONECROSIS; LEG CRAMP; LEUKORRHEA; LOW DRUG DOSE; MORBIDITY; MORTALITY; NIGHT SWEAT; NUTRITION; OSTEOPENIA; OSTEOSARCOMA; PARATHYROID GLAND; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIDE EFFECT; STROKE; SUBSTITUTION THERAPY; THROMBOEMBOLISM; UNITED STATES; URINE INCONTINENCE; UTERUS PROLAPSE; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

BONE DENSITY CONSERVATION AGENTS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79955859547     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-010-9137-1     Document Type: Review

References (59)

1. Taylor H. Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis. Formulary. 2010;45:52-9.
2. Looker AC, Orwell ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-8. (Pubitemid 27500187)
3. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. Frax and its application in clinical practice. Bone. 2009;44:734-43.
4. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Int Med. 2004;164:1108-12. (Pubitemid 38668990)
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteston A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75.
6. Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1451-67.
7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371-88. (Pubitemid 28439961)
8. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842-7.
9. Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000;355:848-9. (Pubitemid 30128839)
10. Evista (Raloxifene HCL) (Package insert). Indianapolis, IN: Eli Lilly and Company, 2007.
11. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY 139481) HCL; impact on bone turnover and serum lipid profile in healthy Postmenopausal women. J Bone Miner Res. 1996;11:835-42. (Pubitemid 26172808)
12. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-7. (Pubitemid 27510100)
13. Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Int Med. 2000;160:3444-50.
14. Jolly EE, Bjarnason NH, Nevan P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause. 2003;10:337-44. (Pubitemid 36870506)
15. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med. 2004;164:871-9. (Pubitemid 38520628)
16. Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999;281:2189-97.
17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA. 1999;282:637-45. (Pubitemid 29384151)
18. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis; four year results from a randomized clinical trial. JAMA. 1999;282:637-45. (Pubitemid 29384151)
19. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-61. (Pubitemid 39654569)
20. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514-24. (Pubitemid 41243540)
21. Neven P, Quail D, Martin F, et al. Comparing raloxifene with continuous combined estrogen-progesterone therapy in postmenopausal women: review of Euralox 1. Maturitas. 2005;52:87-101. (Pubitemid 41368031)
22. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-37. (Pubitemid 44050394)
23. Shelly W, Draper M, Krishman V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163-80.
24. Siris E, Harris S, Eastell R, et al. Effects of raloxifene on the risk of non-vertebral fractures after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2004;19:896.
25. Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene; 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125-34.
26. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA. 2006;295:2727-41.
27. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441-52. (Pubitemid 41368577)
28. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558-65. (Pubitemid 29147076)
29. Duvernoy CS, Kulkarni PM, Dowsett SA, et al. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause. 2005;12:444-52. (Pubitemid 41098658)
30. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837-44. (Pubitemid 40458815)
31. Davies GC, Huster WJ, Shen W, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. 1999;6:188-95. (Pubitemid 29418961)
32. Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol. 2002;85:388-90. (Pubitemid 34523005)
33. Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 2001;98:91-6. (Pubitemid 32622770)
34. Goldstein SR, Johnson S, Watts NB, et al. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause. 2005;12:160-4. (Pubitemid 40464284)
35. Waetjen LE, Brown JS, Modelska K, et al. Effect of raloxifene on urinary incontinence; a randomized controlled trial. Obstet Gynecol. 2004;103:261-6.
36. Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97:520-7. (Pubitemid 43190043)
37. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Eng J Med. 2001;344:1207-13. (Pubitemid 32319495)
38. Yaffe K, Kreuger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162:683-90. (Pubitemid 40489129)
39. Bolognese M, Krege J, Utian W, et al. OC45; Arzoxifene in postmenopausal women with normal or low bone mass. Bone (supplement). 2009;44:S230.
40. Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand. 2006;85:135-42.
41. Vogelvang TE, van der Mooren MJ, et al. Emerging selective estrogen receptor modulators; special focus on effects on coronary heart disease in postmenopausal women. Drugs. 2006;66:191-221. (Pubitemid 43213903)
42. Budzar A, Hayes D, El-Khoudary A, et al. Phase II randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73:161-75. (Pubitemid 34548158)
43. van Rietbergen E, Majumdar S, Newitt D, et al. High-resolution MRI and Micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials; application to calcaneal bone in postmenopausal women after one year of idoxifene treatment. Clin Biomech (Bristol,Avon). 2002;17:81-8. (Pubitemid 34097755)
44. Fleischer AC, Wheeler JE, Yeh IT, et al. Effects of clomoiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. J Ultrasound Med. 1999;18:503-12.
45. Ariazi EA, Ariazi JL, Cordera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6:181-202.
46. Alertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators; a systemic review. Climacteric. 2005;8:214-20. (Pubitemid 41224434)
47. Gardner M, Taylor A, Wei G, et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol. 2006;46:52-8. (Pubitemid 43021713)
48. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377-86.
49. Cummings S, Ensrud K, Delmas P, et al. Lasofoxifene in postmenopausal Women with osteoporosis. N Engl J Med. 2010;362:686-96.
50. Komm BS, Kharode YP, Bodine PV, et al. Bazodoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999-4008. (Pubitemid 41175771)
51. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazodoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol. 2005;105:1397-404. (Pubitemid 40734275)
52. Miller PD, Chines AA, Christiansen C, et al. Effects of bazodeoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525-35. (Pubitemid 351501893)
53. Boss SM, Huster WJ, Neild JA, et al. effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458-64. (Pubitemid 28040243)
54. Komm B. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984-92.
55. Pickar J, I-Tein Y, Bachman G, et al. Endometrial effects of a tissue selective estrogen complex containing bazodoxifene/conjugated estrogens as a menopausal therapy. Fertl Steril 2009;92:1018-1024.
56. Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen modulator, bazodoxifene, with conjugated estrogens as a new paradigmfor the treatment of postmenopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084-91.
57. Lobo R, Pinkerton J, Gass M, et al. Evaluation of bazodoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025-34.
58. Archer D, Lewis V, Carr B, et al. Bazodoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertl Steril. 2009;92:1039-44.
59. Lindsay R, Gallagher J, Kagan R, et al. Efficacy of tissueselective estrogen complex of bazodoxifene/conjugated estrogens for osteoporosis preventionin at-risk postmenopausal women. Fertl Steril. 2009;92:1045-51.